Objective: To observe the effects of Qingnao Yiyuan Decotion in treating acute ischemic stroke, and the influence on serum neuronal specific enolase(NSE) and S100 calcium-binding protein B(S100 B). Methods: A total of 60 hospitalized patients from Department of Encephalopathy in The First Affiliated Hospital of Guangxi University of Chinese Medicine during April 2016 to December 2016 were randomly divided into treatment group and control group, 30 cases in each group. Control group was given western routine therapy, while treatment group was given Qingnao Yiyuan Decoction on the basis of western routine therapy. Enzyme linked immunosorbent assay(ELISA) was used to detect the serum levels of NSE and S100 B of two groups before treatment and 3 days, 7 days, 14 days after treatment, respectively, NIHSS score, TCM syndrome integral, the capability state of life, and the clinical curative effect were evaluated. Results: After treatment, NIHSS score, Chinese clinical syndrome integral, and serum level of NSE and S100 B in the treatment group and control group decreased, and the treatment group decreased more significantly(P<0.05, P<0.01). The capability state of life improved significantly in both groups(P<0.01), the treatment group improved more significantly(P<0.05). Clinical total effective rate in treatment group was significantly higher than that in the control group, clinical total effective rate of two groups were 90.0% and 76.7%, respectively, the difference was statistically significant(P<0.05). Conclusion: Qingnao Yiyuan Decoction can reduce the degree of neurologic impairment of ischemic stroke patients and improve clinical efficacy, the mechanism of which is related to down-regulating serum NSE and S100 B levels.
China Journal of Traditional Chinese Medicine and Pharmacy
Qingnao Yiyuan Decoction
Neuronal specific enolase(NSE)
S100 calcium-binding protein B(S100B)
National Institute of Health Stroke Scale(NIHSS)